S Zimmer1, V Maus1, C Maurer2, A Berlis2, W Weber1, S Fischer3. 1. From the Institut für Diagnostische und Interventionelle Radiologie, Neuroradiologie, Nuklearmedizin (S.Z., V.M., W.W., S.F.), Universitätsklinik, Knappschaftskrankenhaus Bochum-Langendreer, Bochum, Germany. 2. Klinik für Diagnostische Radiologie und Neuroradiologie (C.M., A.B.), Klinikum Augsburg, Augsburg, Germany. 3. From the Institut für Diagnostische und Interventionelle Radiologie, Neuroradiologie, Nuklearmedizin (S.Z., V.M., W.W., S.F.), Universitätsklinik, Knappschaftskrankenhaus Bochum-Langendreer, Bochum, Germany sebif101@googlemail.com.
Abstract
BACKGROUND AND PURPOSE: The safety and efficacy of the Woven EndoBridge (WEB) device has been shown in multiple good clinical practice trials, whereas aneurysm locations in these trials were restricted to bifurcation aneurysms located at the circle of Willis (MCA bifurcation, ICA bifurcation, anterior communicating artery, basilar artery tip). Our aim was to evaluate angiographic and clinical results with the WEB 17 in aneurysm locations that were excluded from the good clinical practice trials, assuming that the angiographic and clinical results are similar to those of the good clinical practice trials for aneurysms in traditional locations. MATERIALS AND METHODS: We performed retrospective analysis of immediate and follow-up results of aneurysms in locations outside the good clinical practice trials in which the WEB 17 was used on an intention-to-treat approach. RESULTS: Between June 2017 and May 2020, forty-seven aneurysms in 44 patients met the inclusion criteria. Aneurysm locations were the ICA posterior communicating artery in 19 (40.3%), the ICA paraophthalmic or choroidal locations in 4 (8.6%), anterior cerebral artery A2 segment in 13 (27.7%), MCA M1 segment in 2 (4.3%), posterior cerebral artery P2 segment in 2 (4.3%), PICA in 3 (6.4%), and the superior cerebellar artery in 4 (8.4%) cases. The procedure-related morbidity and mortality rates in the entire series were 0.0%. The early and late (<12 and >12 months) complete occlusion rates were 63.9% (23/36) and 77.8% (14/18), respectively. CONCLUSIONS: The WEB 17 is safe and effective in aneurysm locations different from the traditional bifurcation aneurysms included in the good clinical practice trials. Further studies will help to define the entire spectrum of aneurysm morphologies and locations suitable for the WEB 17.
BACKGROUND AND PURPOSE: The safety and efficacy of the Woven EndoBridge (WEB) device has been shown in multiple good clinical practice trials, whereas aneurysm locations in these trials were restricted to bifurcation aneurysms located at the circle of Willis (MCA bifurcation, ICA bifurcation, anterior communicating artery, basilar artery tip). Our aim was to evaluate angiographic and clinical results with the WEB 17 in aneurysm locations that were excluded from the good clinical practice trials, assuming that the angiographic and clinical results are similar to those of the good clinical practice trials for aneurysms in traditional locations. MATERIALS AND METHODS: We performed retrospective analysis of immediate and follow-up results of aneurysms in locations outside the good clinical practice trials in which the WEB 17 was used on an intention-to-treat approach. RESULTS: Between June 2017 and May 2020, forty-seven aneurysms in 44 patients met the inclusion criteria. Aneurysm locations were the ICA posterior communicating artery in 19 (40.3%), the ICA paraophthalmic or choroidal locations in 4 (8.6%), anterior cerebral artery A2 segment in 13 (27.7%), MCA M1 segment in 2 (4.3%), posterior cerebral artery P2 segment in 2 (4.3%), PICA in 3 (6.4%), and the superior cerebellar artery in 4 (8.4%) cases. The procedure-related morbidity and mortality rates in the entire series were 0.0%. The early and late (<12 and >12 months) complete occlusion rates were 63.9% (23/36) and 77.8% (14/18), respectively. CONCLUSIONS: The WEB 17 is safe and effective in aneurysm locations different from the traditional bifurcation aneurysms included in the good clinical practice trials. Further studies will help to define the entire spectrum of aneurysm morphologies and locations suitable for the WEB 17.
Authors: Sbt van Rooij; M E Sprengers; J P Peluso; J Daams; D Verbaan; W J van Rooij; C B Majoie Journal: Interv Neuroradiol Date: 2020-02-06 Impact factor: 1.610
Authors: David Fiorella; Andrew Molyneux; Alexander Coon; Istvan Szikora; Isil Saatci; Feyyaz Baltacioglu; Ali Sultan; Adam Arthur Journal: J Neurointerv Surg Date: 2017-01-17 Impact factor: 5.836
Authors: Adam S Arthur; Andy Molyneux; Alexander L Coon; Isil Saatci; Istvan Szikora; Feyyaz Baltacioglu; Ali Sultan; Daniel Hoit; Josser E Delgado Almandoz; Lucas Elijovich; Saru Cekirge; James V Byrne; David Fiorella Journal: J Neurointerv Surg Date: 2019-04-16 Impact factor: 5.836
Authors: Stefan Schob; Richard Brill; Eberhard Siebert; Massimo Sponza; Marie-Sophie Schüngel; Walter Alexander Wohlgemuth; Nico Götz; Dirk Mucha; Anil Gopinathan; Maximilian Scheer; Julian Prell; Georg Bohner; Vladimir Gavrilovic; Martin Skalej Journal: Front Neurol Date: 2022-01-06 Impact factor: 4.003